Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks to buy or sell: From Lupin to NTPC— Ajit Mishra of Religare Broking suggests strategies for these 3 shares
Ajit Mishra of Religare Broking provides crucial insights for navigating the current tumultuous market. With the Nifty 50 experiencing declines, he highlights opportunities in stocks like Lupin and NTPC.
Could the West Asia conflict drag Nifty 50 down to 22,000?
Whether the Nifty 50 recovers from here or drops further to 22,000 depends heavily on the duration of the current geopolitical crisis and the resulting oil shock. Let's take a closer look at landscape.
Avoid chasing metal rally; focus on domestic sectors: Jyotivardhan Jaipuria
Jyotivardhan Jaipuria, Founder & MD of Valentis Advisors, says market corrections during geopolitical conflicts historically present buying opportunities, though investors should stagger investments due to oil and gas risks. He remains positive on banks, select capital goods and pharmaceuticals, while continuing to hold metals but avoiding fresh buying at current levels. Export-oriented sectors like chemicals may face near-term pressure from higher logistics and raw material costs.
Lupin shares hit 52-week high after registering gains for six consecutive months
Lupin is on track to hit $1 billion in US sales this fiscal year. Its US revenue guidance is above $1 billion for the financial year 2027. Its margins are estimated to be between 26% - 27% for the current year and 25% for the next year as research and development (R&D) expenses rise.
Niva Bupa gets IRDAI show cause notice after inspection
Niva Bupa Health Insurance received a Show Cause Notice and Letter of Advice from IRDAI after a February 2025 inspection, confirming compliance steps and no current impact on operations.
Why the Brooks Steriscience–OneSource deal was called off
OneSource Specialty Pharma said its board decided not to proceed 'in its current form' as it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance